Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 1972, Sofinnova Partners is a prominent venture capital firm headquartered in Paris, with additional offices in London and Milan. The firm specializes in life sciences, particularly in biopharma, medtech, digital medicine, agriculture, and industrial processes. Over its 50 years of operation, Sofinnova Partners has amassed over €4 billion in assets under management and has backed more than 500 companies, establishing itself as one of the longest-standing life sciences VCs globally.
Sofinnova Partners operates a multi-strategy platform that encompasses early-stage investments, growth-stage funding, and crossover investments. This diverse approach allows the firm to support companies throughout their lifecycle, from inception to growth. The firm has invested in 151 companies as of September 2025, demonstrating its active role in the venture capital landscape.
Notable milestones include the recent closing of Sofinnova Capital XI in November 2025, which raised €650 million (~$750 million), significantly exceeding its initial target. The firm’s LP base includes pharmaceutical companies, insurers, and sovereign wealth funds, reflecting its strong connections within the industry.
Sofinnova Partners invests across the entire value chain of life sciences, focusing on sectors such as biopharma, medtech, digital medicine, agriculture, and industrial processes. The firm’s investment strategies include:
The firm typically invests between $1 million and $175 million, allowing for flexibility in supporting companies at various stages. Sofinnova Partners emphasizes deep clinical and regulatory expertise, which enhances its ability to guide portfolio companies through critical milestones.
Sofinnova Partners has a diverse portfolio that includes notable companies across various sectors of life sciences. Key portfolio companies include:
These companies exemplify Sofinnova's commitment to supporting innovation in healthcare and life sciences. The firm’s portfolio reflects its focus on addressing critical health challenges through advanced technologies and sustainable practices.
Antoine Papiernik - Chairman & Managing Partner. Antoine has been with Sofinnova Partners since its inception and has extensive experience in life sciences venture capital.
Henrijette Richter - Managing Partner. Henrijette brings a wealth of knowledge in healthcare investments and has played a key role in the firm’s growth.
Graziano Seghezzi - Managing Partner. Graziano is known for his expertise in biopharma and medtech investments, contributing significantly to the firm’s portfolio.
Maina Bhaman - Partner, Capital Strategy. Maina focuses on capital strategy and has a strong background in financial analysis and investment management.
Michael Krel - Partner, Industrial Biotech Strategy. Michael specializes in industrial biotech investments and has a deep understanding of sustainable technologies.
Cécile Dupont - Partner, MD Start Strategy. Cécile leads the MD Start accelerator program, focusing on medtech innovation.
Jacques Theurillat - Partner, Crossover Strategy. Jacques is involved in late-stage investments and has a strong track record in managing crossover funds.
To pitch Sofinnova Partners, founders should use the project submission form available on their website. It is essential to include a comprehensive deck that outlines the business model, market analysis, and financial projections. Response times may vary, but founders can expect feedback within a few weeks.
Warm introductions are preferred, as they can facilitate a more favorable review process. Founders are encouraged to highlight any unique aspects of their technology or approach that differentiate them from competitors.
Sofinnova Partners operates several notable programs aimed at fostering innovation in life sciences:
These programs are designed to support early-stage companies and drive innovation in the life sciences sector.
In November 2025, Sofinnova Partners closed its flagship fund, Sofinnova Capital XI, raising €650 million (~$750 million), significantly exceeding its initial target. This fund focuses on early-stage biopharma and medtech investments.
In May 2025, Sofinnova led a $65 million Series A investment in HAYA Therapeutics, a company developing precision RNA-guided medicines for chronic and age-related diseases. The firm also participated in a $100 million Series C round for Galvanize, alongside Janus Henderson and T. Rowe Price.
Additionally, Sofinnova Partners was involved in a $91 million Series A extension for T-Therapeutics, which focuses on TCR therapeutics for cancer and autoimmune diseases, and participated in a $141 million Series B for AAVantgarde, a company developing treatments for inherited retinal diseases.
What are Sofinnova Partners' investment criteria?
Sofinnova Partners focuses exclusively on life sciences, investing in biopharma, medtech, digital medicine, agriculture, and industrial processes. They seek companies at various stages, from seed to growth, with a strong emphasis on innovation and sustainability.
How can I pitch to Sofinnova Partners?
Founders can submit their projects through the contact page on the Sofinnova Partners website. A project submission form is available for potential investments, and it is advisable to include a detailed business plan and financial projections.
What makes Sofinnova Partners different from other VCs?
The firm offers deep clinical and regulatory expertise, which is crucial for navigating the complexities of the life sciences sector. Their hands-on support throughout milestones and access to a strong transatlantic syndicate further differentiate them from other investors.
What is the geographic focus of Sofinnova Partners?
Sofinnova Partners primarily focuses on Europe but is open to global investments, leveraging its strong connections in the transatlantic market.
What is the typical check size for investments?
Sofinnova Partners typically invests between $1 million and $175 million, allowing them to support companies at various stages of development.
What kind of post-investment involvement can founders expect?
Founders can expect hands-on support from Sofinnova Partners, including guidance through clinical and regulatory processes, strategic advice, and access to their extensive network within the life sciences industry.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.